At the annual ASCO meeting in June 2012, we presented data from our ALN-VSP Phase I extension study. Overall, the results demonstrated disease control lasting more than six months in the majority of patients treated on the extension study, including a complete response (CR) in an endometrial cancer patient who had multiple liver metastases.

Results from the extension study also give us increased confidence in long-term chronic dosing with RNAi therapeutics delivered via LNPs, as patients have received drug twice a month for up to nearly two years, and approximately 11 months on average.  In this study, chronic dosing of up to 23 months with ALN-VSP was found to be generally safe and well tolerated.

If you’re at ASCO, our poster can be viewed today in the Development Therapeutics-Experimental Therapeutics poster session from 8 AM-12 PM CDT.